Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Forecasted to Post Q2 2024 Earnings of ($0.65) Per Share

Lexeo Therapeutics, Inc. (NASDAQ:LXEOFree Report) – Investment analysts at HC Wainwright issued their Q2 2024 earnings per share estimates for Lexeo Therapeutics in a research note issued on Thursday, June 6th. HC Wainwright analyst M. Kapoor anticipates that the company will earn ($0.65) per share for the quarter. HC Wainwright has a “Buy” rating and a $22.00 price target on the stock. The consensus estimate for Lexeo Therapeutics’ current full-year earnings is ($2.65) per share. HC Wainwright also issued estimates for Lexeo Therapeutics’ Q3 2024 earnings at ($0.68) EPS, Q4 2024 earnings at ($0.70) EPS, FY2024 earnings at ($2.79) EPS, Q1 2025 earnings at ($0.73) EPS, Q2 2025 earnings at ($0.77) EPS, Q3 2025 earnings at ($0.82) EPS, Q4 2025 earnings at ($0.88) EPS and FY2025 earnings at ($3.20) EPS.

Lexeo Therapeutics (NASDAQ:LXEOGet Free Report) last released its earnings results on Thursday, May 9th. The company reported ($0.77) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.01).

Lexeo Therapeutics Stock Performance

Lexeo Therapeutics stock opened at $17.25 on Monday. The firm has a market capitalization of $568.22 million and a P/E ratio of -0.77. The stock has a fifty day moving average price of $13.93 and a 200 day moving average price of $14.58. Lexeo Therapeutics has a 52 week low of $9.00 and a 52 week high of $22.33. The company has a current ratio of 9.16, a quick ratio of 9.16 and a debt-to-equity ratio of 0.01.

Institutional Investors Weigh In On Lexeo Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets acquired a new stake in Lexeo Therapeutics during the first quarter worth about $75,000. American International Group Inc. acquired a new stake in Lexeo Therapeutics during the first quarter worth about $79,000. Cornell University acquired a new stake in Lexeo Therapeutics during the first quarter worth about $1,980,000. Vanguard Group Inc. increased its stake in Lexeo Therapeutics by 15.8% during the first quarter. Vanguard Group Inc. now owns 481,755 shares of the company’s stock worth $7,554,000 after acquiring an additional 65,573 shares during the last quarter. Finally, RA Capital Management L.P. acquired a new stake in Lexeo Therapeutics during the first quarter worth about $10,364,000. 60.67% of the stock is currently owned by institutional investors and hedge funds.

About Lexeo Therapeutics

(Get Free Report)

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.

Featured Stories

Earnings History and Estimates for Lexeo Therapeutics (NASDAQ:LXEO)

Receive News & Ratings for Lexeo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexeo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.